New chemicals drive mesenchymal stem cells towards cardiac cells

Recent Patents on Regenerative Medicine

Volumn 3, Issue 1, 2013, Pages 47-55

  Vincenzo, Lionetti ^a,b,d   Ventura, Carlo ^c  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^d CNR   (Italy)

Author keywords

Cardiac cells; Cardiac fate; Chemical agents; Drug discovery; Heart; Pre differentiation; Stem cells

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BUTYRIC ACID; CASPASE 3; CHEMICAL AGENT; CYCLIN DEPENDENT KINASE 9; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; HEPATOCYTE NUCLEAR FACTOR 3BETA; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYALURONIC ACID; HYDRAZONE DERIVATIVE; MESSENGER RNA; MICRORNA; NEU DIFFERENTIATION FACTOR; NITRIC OXIDE; OXYTOCIN; RETINOIC ACID; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX17;

ARTICLE; CELL DIFFERENTIATION; GENE EXPRESSION; HEART MUSCLE CELL; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE;

EID: 84875365499     PISSN: 22102965     EISSN: 22102973     Source Type: Journal    
DOI: 10.2174/2210296511303010047     Document Type: Article

References (105)

1. Barile L, Lionetti V. Prometheus's Heart: What lies beneath. J Cell Mol Med 2012; 16: 228-36.
2. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé-Heider F, Walsh S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009; 324: 98-102.
3. Altarche-Xifró W, Curato C, Kaschina E, Grzesiak A, Slavic S, Dong J, et al. Cardiac c-kit+AT2+ cell population is increased in response to ischemic injury and supports cardiomyocyte perform-ance. Stem Cells 2009; 27: 2488-97.
4. Leri A, Kajstura J, Anversa P. Role of cardiac stem cells in cardiac pathophysiology: A paradigm shift in human myocardial biology. Circ Res 2011; 109: 941-61.
5. Lionetti V. How resident stem cells communicate with cardiac cells in beating heart? J Stem Cell Res Ther 2011; 1: e104.
6. Kubo H, Jaleel N, Kumarapeli A, Berretta RM, Bratinov G, Shan X, et al. Increased cardiac myocyte progenitors in failing human hearts. Circulation 2008; 118: 649-57.
7. Martin-Rendon E, Brunskill S, Dorée C, Hyde C, Watt S, Mathur A, et al. Stem cell treatment for acute myocardial infarction. Coch-rane Database Syst Rev 2008; 4: CD006536.
8. Wen Y, Meng L, Xie J, Ouyang J. Direct autologous bone marrow-derived stem cell transplantation for ischemic heart disease: a meta-analysis. Expert Opin Biol Ther 2011; 11: 559-67.
9. Sun L, Zhang T, Lan X, Du G. Effects of stem cell therapy on left ventricular remodeling after acute myocardial infarction: A meta-analysis. Clin Cardiol 2010; 33: 296-302.
10. van der Spoel TI, Jansenof Lorkeers SJ, Agostoni P, van Belle E, Gyöngyösi M, Sluijter JP, et al. Human relevance of pre-clinical studies in stem cell therapy: Systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res 2011; 91: 649-58.
11. Simioniuc A, Campan M, Lionetti V, Marinelli M, Aquaro GD, Cavallini C, et al. Placental stem cells pre-treated with a hyaluronan mixed ester of butyric and retinoic acid to cure infarc-ted pig hearts: A multimodal study. Cardiovasc Res 2011; 90: 546-56.
12. Fukushima S, Varela-Carver A, Coppen SR, Yamahara K, Felkin LE, Lee J, et al. Direct intramyocardial but not intracoronary injec-tion of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation 2007; 115: 2254-61.
13. Robey TE, Saiget MK, Reinecke H, Murry CE. Systems ap-proaches to preventing transplanted cell death in cardiac repair. J Mol Cell Cardiol 2008; 45: 567-81.
14. Campan M, Lionetti V, Aquaro GD, Forini F, Matteucci M, Van-nucci L, et al. Ferritin as a reporter gene for in vivo tracking of stem cells by 1.5-T cardiac MRI in a rat model of myocardial in-farction. Am J Physiol Heart Circ Physiol 2011; 300: H2238-50.
15. Malouf NN, Coleman WB, Grisham JW, Lininger RA, Madden VJ, Sproul M, et al. Adult-derived stem cells from the liver become myocytes in the heart in vivo. Am J Pathol 2001; 158: 1929-35.
16. Synnergren J, Améen C, Jansson A, Sartipy P. Global transcrip-tional profiling reveals similarities and differences between human stem cell derived cardiomyocyte clusters and heart tissue. Physiol Genomics 2012; 44: 245-58.
17. Chen CT, Hsu SH, Wei YH. Mitochondrial bioenergetic function and metabolic plasticity in stem cell differentiation and cellular re-programming. Biochim Biophys Acta 2012; 1820: 571-6.
18. San Martin N, Cervera AM, Cordova C, Covarello D, McCreath KJ, Galvez BG. Mitochondria determine the differentiation poten-tial of cardiac mesoangioblasts. Stem Cells 2011; 29: 1064-74.
19. Tao Y, Neppl RL, Huang ZP, Chen J, Tang RH, Cao R, et al. The histone methyltransferase Set7/9 promotes myoblast differentiation and myofibril assembly. J Cell Biol 2011; 194: 551-65.
20. Cui K, Zang C, Roh TY, Schones DE, Childs RW, Peng W, et al. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 2009; 4: 80-93.
21. Lionetti V, Cantoni S, Cavallini C, Bianchi F, Valente S, Frascari I, et al. Hyaluronan mixed esters of butyric and retinoic acid afford-ing myocardial survival and repair without stem cell transplanta-tion. J Biol Chem 2010; 285: 9949-61.
22. Burba I, Colombo GI, Staszewsky LI, De Simone M, Devanna P, Nanni S, et al. Histone deacetylase inhibition enhances self renewal and cardioprotection by human cord blood-derived CD34 cells. PLoS One 2011; 6: e22158.
23. Kaichi S, Hasegawa K, Takaya T, Yokoo N, Mima T, Kawamura T, et al. Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. Cardiovasc Res 2010; 88: 314-23.
24. Sluijter JP, van Mil A, van Vliet P, Metz CH, Liu J, Doevendans PA, et al. MicroRNA-1 and-499 regulate differentiation and pro-liferation in human-derived cardiomyocyte progenitor cells. Arte-rioscler Thromb Vasc Biol 2010; 30: 859-68.
25. Hosoda T, Zheng H, Cabral-da-Silva M, Sanada F, Ide-Iwata N, Ogórek B, et al. Human cardiac stem cell differentiation is regu-lated by a mircrine mechanism. Circulation 2011; 123: 1287-96.
26. Ma J, Guo L, Fiene SJ, Anson BD, Thomson JA, Kamp TJ, et al. High purity human-induced pluripotent stem cell-derived cardio-myocytes: Electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 2011; 301: H2006-17.
27. van Vliet P, de Boer TP, van der Heyden MA, El Tamer MK, Slui-jter JP, Doevendans PA, et al. Hyperpolarization induces differen-tiation in human cardiomyocyte progenitor cells. Stem Cell Rev 2010; 6: 178-85.
28. Chu L, Hao H, Luo M, Huang Y, Chen Z, Lu T, et al. Ox-LDL modifies the behaviour of bone marrow stem cells and impairs their endothelial differentiation via inhibition of Akt phosphorylation. J Cell Mol Med 2011; 15: 423-32.
29. Cantoni S, Cavallini C, Bianchi F, Bonavita F, Vaccari V, Olivi E, et al. Rosuvastatin elicits KDR-dependent vasculogenic response of human placental stem cells through PI3K/AKT pathway. Pharma-col Res 2012; 65: 275-84.
30. Ventura C, Cavallini C, Bianchi F, Cantoni S. Stem cells and car-diovascular repair: A role for natural and synthetic molecules har-boring differentiating and paracrine logics. Cardiovasc Hematol Agents Med Chem 2008; 6: 60-8.
31. Lionetti V, Bianchi G, Recchia FA, Ventura C. Control of autocrine and paracrine myocardial signals: An emerging therapeu-tic strategy in heart failure. Heart Fail Rev 2010; 15: 531-42.
32. Willems E, Lanier M, Forte E, Lo F, Cashman J, Mercola M. A chemical biology approach to myocardial regeneration. J Cardio-vasc Transl Res 2011; 4: 340-50.
33. Ivashchenko CY. Human embryonic and induced pluripotent stem cells in cardiovascular drug discovery: Patents and patented uses. Recent Pat Cardiovasc Drug Discov 2011; 6: 199-206.
34. Jakob M, Thum T. Recent patents on cardiovascular stem cells. Recent Pat Cardiovasc Drug Discov 2008; 3: 59-72.
35. Hariri, R.J. Placental stem cell populations. US8057788 (2011).
36. Edinger, J., Ye, Q., Wang, J., Hariri, R.J. Placental stem cell popu-lations. US8202703 (2012).
37. Rosen, M.R., Robinson, R.B., Cohen, I.S., Brink, P.R., Gaudette, G., Potapova, I. Differentiation of human mesenchymal stem cells to cardiac progenitor cells that promote cardiac repair. US20060198829 (2006).
38. Barnett P, van den Hoff MJ. Cardiac regeneration: different cells same goal. Med Biol Eng Comput 2011; 49: 723-32.
39. Koninckx R, Daniëls A, Windmolders S, Carlotti F, Mees U, Steels P, et al. Mesenchymal stem cells or cardiac progenitors for cardiac repair? A comparative study. Cell Mol Life Sci 2011; 68: 2141-56.
40. Behfar A, Faustino RS, Arrell DK, Dzeja PP, Perez-Terzic C, Ter-zic A. Guided stem cell cardiopoiesis: Discovery and translation. J Mol Cell Cardiol 2008; 45: 523-9.
41. Williams AR, Hare JM. Mesenchymal stem cells: Biology, patho-physiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011; 109: 923-40.
42. Sadek H, Hannack B, Choe E, Wang J, Latif S, Garry MG, et al. Cardiogenic small molecules that enhance myocardial repair by stem cells. Proc Natl Acad Sci USA 2008; 105: 6063-8.
43. Olson, E., Frantz, D., Hsieh, J., McKnight, S.L., Schneider, J. Stem cell differentiating agents and uses therefor. US20090076103 (2009).
44. Quattrocelli M, Palazzolo G, Agnolin I, Martino S, Bouché M, Anastasia L, et al. Synthetic sulfonyl-hydrazone-1 positively regu-lates cardiomyogenic microRNA expression and cardiomyocyte differentiation of induced pluripotent stem cells. J Cell Biochem 2011; 112: 2006-14.
45. Bostjancic E, Zidar N, Stajer D, Glavac D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 2010; 115: 163-9.
46. Mercola, M., Dawson, M., Cashman, J. Small molecule compounds for stem cell differentiation. US20100159596 (2010).
47. Bouchez LC, Boitano AE, de Lichtervelde L, Romeo R, Cooke MP, Schultz PG. Small-molecule regulators of human stem cell self-renewal. Chembiochem 2011; 12: 854-7.
48. Kaichi S, Takaya T, Morimoto T, Sunagawa Y, Kawamura T, Ono K, et al. Cyclin-dependent kinase 9 forms a complex with GATA4 and is involved in the differentiation of mouse ES cells into car-diomyocytes. J Cell Physiol 2011; 226: 248-54.
49. Molkentin JD, Lin Q, Duncan SA, Olson EN. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev 1997; 11: 1061-72.
50. Luesch, H., Kanchan, T., Paul, V.J. Macrocyclic compounds and methods of treatment. US20110118323 (2011).
51. Ying Y, Taori K, Kim H, Hong J, Luesch H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc 2008; 130: 8455-9.
52. Cole KE, Dowling DP, Boone MA, Phillips AJ, Christianson DW. Structural basis of the antiproliferative activity of largazole, a dep-sipeptide inhibitor of the histone deacetylases. J Am Chem Soc 2011; 133: 12474-7.
53. Lee SU, Kwak HB, Pi SH, You HK, Byeon SR, Ying Y, et al. In vitro and in vivo osteogenic activity of largazole. ACS Med Chem Lett 2011; 2: 248-51.
54. Yang G, Tian J, Feng C, Zhao LL, Liu Z, Zhu J. Trichostatin A promotes cardiomyocyte differentiation of rat mesenchymel stem cells after 5-azacytidine induction or during co-culture with neona-tal cardiomyocytes via a mechanism independent of histone deace-tylase inhibition. Cell Transplant 2011. [Epub ahead of print].
55. Perbellini, A., Coradini, D. Mixed esters of hyaluronic acid with retinoic and butyric acids. WO2004056877 (2004) & US20060074048 (2006).
56. Perbellini, A., Ventura, C., Maioli, M. Use of retinoic esters of hyaluronic acid for the differentiation of totipotent stem cells. US20060216820 (2006).
57. Ventura C, Maioli M, Asara Y, Santoni D, Scarlata I, Cantoni S, et al. Butyric and retinoic mixed ester of hyaluronan. A novel dif-ferentiating glycoconjugate affording a high throughput of cardio-genesis in embryonic stem cells. J Biol Chem 2004; 279: 23574-9.
58. Ventura C, Cantoni S, Bianchi F, Lionetti V, Cavallini C, Scarlata I, et al. Hyaluronan mixed esters of butyric and retinoic acid drive ardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts. J Biol Chem 2007; 282: 14243-52.
59. Simioniuc A, Campan M, Lionetti V, Marinelli M, Aquaro GD, Cavallini C, et al. Placental stem cells pre-treated with a hyaluronan mixed ester of butyric and retinoic acid to cure infarc-ted pig hearts: A multimodal study. Cardiovasc Res 2011; 90: 546-56.
60. Maioli M, Santaniello S, Montella A, Bandiera P, Cantoni S, Cavallini C, et al. Hyaluronan esters drive Smad gene expression and signaling enhancing cardiogenesis in mouse embryonic and human mesenchymal stem cells. PLoS One 2010; 5: e15151.
61. Song L, Yan W, Chen X, Deng CX, Wang Q, Jiao K. Myocardial smad4 is essential for cardiogenesis in mouse embryos. Circ Res 2007; 101: 277-85.
62. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26: 5420-32.
63. Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem 2004; 93: 57-67.
64. Trivedi CM, Luo Y, Yin Z, Zhand M, Zhu W, Wang T, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007; 13: 324-31.
65. Gregoire S, Xiao L, Nie J, Zhang X, Xu M, Li J, et al. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol 2007; 27: 1280-95.
66. Martin M, Kettmann R, Dequiedt F. Class II histone deacetylases: Regulating the regulators. Oncogene 2007; 26: 5450-67.
67. deRuijter A J, van Gennip A H, Caron H N, Kemp S, vanKuilen-burg A B. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003; 370: 737-49.
68. Bertos N R, Wang A H, Yang X J. Class II histone deacetylases: Structure, function, and regulation. Biochem Cell Biol 2001; 79: 243-52.
69. Miska EA, Karisson C, Langley E, Nielson S J, Pines J, Kouzarides T: HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J 1999; 18: 5099-107.
70. Potthoff M J, Wu H, Arnold MA, Shelton J M, Backs J, McAnally J, et al. Histone deacetylase degradation and MEF2 activation pro-mote the formation of slow-twitch myofiers. J Clin Invest 2007;117: 2459-67.
71. Lu J, McKinsey TA, Nicol RL, Olson EN. Signal-dependent acti-vation of the MEF2 transcription factor by disassociation from his-tone deacetylases. Proc Natl Acad Sci USA 2000; 97: 4070-5.
72. Zhao X, Ito A, Kane CD, Liao TS, Bolger TA, Lemrow S M, et al. The modular nature of histone deacetylase HDAC4 confers phos-phorylation-dependent intracellular trafficking. J Biol Chem 2001; 276: 35042-8.
73. Yang X J, Gregoire S. Class II histone deacetylases: From se-quence to function, regulation, and clinical implication. Mol Cell Biol 2005; 25: 2873-84.
74. Michishita E, Park J Y, Bumeskis J M, Barrett J C, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005; 16: 4623-35.
75. Gregoire S, Xiao L, Nie J, Zhang X, Xu M, Li J, et al. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol 2007; 27: 1280-95.
76. Anversa, P., Leri, A., Kajstura, J. Compositions comprising HDAC inhibitors and methods of their use in restoring stem cells function and preventing heart failure. US20090162329 (2009).
77. Zhou, M. Neuregulin and cardiac stem cells. US20110229444 (2011).
78. Zhu WZ, Xie Y, Moyes KW, Gold JD, Askari B, Laflamme MA. Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. Circ Res 2010; 107: 776-86.
79. Sun M, Yan X, Bian Y, Caggiano AO, Morgan JP. Improving murine embryonic stem cell differentiation into cardiomyocytes with neuregulin-1: Differential expression of microRNA. Am J Physiol Cell Physiol 2011; 301: C21-30.
80. Fisher DZ, Chaudhary N, Blobel G. cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Natl Acad Sci USA 1986; 83: 6450-4.
81. Lin F, Worman HJ. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem 1993; 268: 16321-6.
82. Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M. The processing pathway of prelamin A. J Cell Sci 1994; 107: 61-7.
83. Brodsky, G. Prelamin a pre peptide as a universal stem cell differ-entiation signal. US20090175836 (2009).
84. Saga Y, Kitajima S, Miyagawa-Tomita S. Mesp1 expression is the earliest sign of cardiovascular development. Trends Cardiovasc Med 2000; 10: 345-52.
85. Blanpain, C., Bondue, A., Lapouge, G. Mesp1 as a master regulator of multipotent cardiovascular progenitor specification and uses. US20100330044 (2010).
86. Utz PJ, Anderson P. Life and death decisions: Regulation of apop-tosis by proteolysis of signaling molecules. Cell Death Differ 2000; 7: 589-602.
87. Cardone MH, Salvesen GS, Widmann C, Johnson G, Frisch SM. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 1997; 90: 315-23
88. Chaudhary PM, Eby MT, Jasmin A, Hood L. Activation of the c-Jun N-terminal kinase/stress-activated protein kinase pathway by overexpression of caspase-8 and its homologs. J Biol Chem 1999; 274: 19211-9.
89. Fernando P, Kelly JF, Balazsi K, Slack RS, Megeney LA. Caspase 3 activity is required for skeletal muscle differentiation. Proc Natl Acad Sci USA 2002; 99: 11025-30.
90. Mageney, L., Ottawa, F. Modulation of stem cell differentiation by modulation of caspase-3 activity. US20060013804 (2006).
91. 2+ channel during car-diomyogenesis: Switch from NO to adenylyl cyclase-mediated in-hibition. FASEB J 1999; 13: 313-24.
92. Bloch W, Fleischmann BK, Lorke DE, Andressen C, Hops B, Hescheler J, et al. Nitric oxide synthase expression and role during cardiomyogenesis. Cardiovasc Res 1999; 43: 675-84.
93. Kanno S, Kim PK, Sallam K, Lei J, Billiar TR, Shears LL 2nd. Nitric oxide facilitates cardiomyogenesis in mouse embryonic stem cells. Proc Natl Acad Sci USA 2004; 101: 12277-81.
94. Spallotta F, Rosati J, Straino S, Nanni S, Grasselli A, Ambrosino V, et al. Nitric oxide determines mesodermic differentiation of mouse embryonic stem cells by activating class IIa histone deacety-lases: Potential therapeutic implications in a mouse model of hindlimb ischemia. Stem Cells 2010; 28: 431-42.
95. Rebelatto CK, Aguiar AM, Senegaglia AC, Aita CM, Hansen P, Barchiki F, et al. Expression of cardiac function genes in adult stem cells is increased by treatment with nitric oxide agents. Bio-chem Biophys Res Commun 2009; 378: 456-61.
96. Berardi GR, Rebelatto CK, Tavares HF, Ingberman M, Shigunov P, Barchiki F, et al. Transplantation of SNAP-treated adipose tissue-derived stem cells improves cardiac function and induces neovas-cularization after myocardium infarct in rats. Exp Mol Pathol 2011; 90: 149-56.
97. Gutkowska, J., Paquin, J., Danalache, B.A., Jankowski, M. Oxyto-cin as cardiomyogenesis inducer and uses. US20060205636 (2006).
98. Danalache BA, Paquin J, Donghao W, Grygorczyk R, Moore JC, Mummery CL, et al. Nitric oxide signaling in oxytocin-mediated cardiomyogenesis. Stem Cells 2007;25: 679-88.
99. Burba I, Devanna P, Pesce M. When cells become a drug. Endothe-lial progenitor cells for cardiovascular therapy: Aims and reality. Recent Pat Cardiovasc Drug Discov 2010; 5: 1-10.
100. Kim, J.B., Zaehres, H., Scholer, H.R. Generation of induced pluri-potent stem (iPS) cells. US20110154518 (2011).
101. Ikeda, Y., Terzic, A., Nelson, T.J., Mael, A.A., Martinez Fernan-dez, A.J., Yamada, S. Induced pluripotent stem cells. US20110200568 (2011).
102. Dohoon, K., Chun-hyung, K., Kwang-soo, K. Induced pluripotent stem cells. US20120128655 (2012).
103. Yamanaka, S., Takahashi, K., Nakagawa, M. Nuclear reprogram-ming factor and induced pluripotent stem cells. US20090047263 (2009).
104. Tezuka, K., Shibata, T., Kunisada, T., Tamaoki, N., Takeda, T., Yamanaka, S., Takahashi, K. Efficient method for establishing in-duced pluripotent stem cells. US20110201110 (2011).
105. Shi, Y., Desponts, C., Lin, T., Li, W., Zhu, S., Ding, S. Chemical approaches for generation of induced pluripotent stem cells. US20100267141 (2010).